Roche signs exclusive distribution deal with DxS for K-RAS and EGFR Cancer Mutation Tests

Roche and DxS Ltd based in Manchester, have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test. The tests are intended, when considered with other clinically relevant factors, to aid doctors in identifying suitable patients likely to benefit from a specific cancer therapy based on their mutation status. Daniel O'Day, President and CEO of Roche said 'There is growing demand for tests to indicate prognosis and identify patient groups more likely to benefit from a particular drug'.

^Back to Top